Details of the Drug Combination

General Information of Drug Combination (ID: DCYWBCL)

• Drug Combination Name: LY03004 + Rufinamide
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  LY03004 (DME5TUR): N.A.
  Rufinamide (DMWE60C): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 13.31
  Bliss Independence Score: 13.31
  Loewe Additivity Score: 27.74
  LHighest Single Agent (HSA) Score: 27.74

Molecular Interaction Atlas of This Drug Combination

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[2]

Indication(s) of Rufinamide

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved (orphan drug)	[3]
Pediatric lennox-gastaut syndrome	8A62.1	Approved	[4]
Seizure disorder	8A6Z	Approved	[3]

Rufinamide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[5]

Rufinamide Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Carboxylesterase 1 (CES1)	DEB30C5	EST1_HUMAN	Metabolism	[6]
Carboxylesterase 2 (CES2)	DETHCPD	EST2_HUMAN	Metabolism	[6]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7470).
• [4] Clinical pipeline report, company report or official report of Eisai.
• [5] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [6] Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.